Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
June 08, 2017 06:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., June 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has commenced its phase 3 clinical program to evaluate the efficacy of...
Inovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study
June 07, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., June 07, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) protected against Zika virus-induced damage...
Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 Checkpoint Inhibitor
June 01, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., June 01, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical collaboration with Genentech, a member of the Roche Group, for advanced...
Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study
May 24, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., May 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of...
Inovio Pharmaceuticals Reports 2017 First Quarter Financial Results
May 10, 2017 16:05 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended March 31, 2017. Total revenue was $10.4...
Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
May 10, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced MedImmune, AstraZeneca’s global biologics research and development arm, will start a...
Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
May 08, 2017 07:30 ET
|
Inovio Pharmaceuticals; Regeneron Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa. and TARRYTOWN, N.Y., May 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced a clinical...
Inovio Pharmaceuticals to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference
May 02, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., May 02, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will participate in the Bank of America Merrill Lynch 2017 Healthcare...
Inovio Pharmaceuticals to Report First Quarter 2017 Financial Results May 10, 2017
April 26, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 first...
Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
April 24, 2017 08:00 ET
|
Inovio Pharmaceuticals
New study expands VGX-3100 program for evaluating therapeutic applications in HPV-related pre-cancers with high medical need VGX-3100 previously demonstrated efficacy in regressing...